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Abstract 
Hereditary haemorrhagic telangiectasia, inherited as an autosomal dominant trait, affects 
approximately 1 in 5,000 people. The abnormal vascular structures in HHT result from 
mutations in genes (most commonly endoglin or ACVRL1) whose protein products influence 
TGF-ß superfamily signalling in vascular endothelial cells. The cellular mechanisms 
underlying the generation of HHT telangiectasia and arteriovenous malformations are being 
unravelled, with recent data focussing on a defective response to angiogenic stimuli in 
particular settings. For affected individuals, there is often substantial morbidity due to 
sustained and repeated haemorrhages from telangiectasia in the nose and gut.  Particular 
haematological clinical challenges include the management of severe iron deficiency 
anaemia; handling the intricate balance of antiplatelet or anticoagulants for HHT patients in 
whom there are often compelling clinical reasons to use such agents; and evaluation of 
apparently attractive experimental therapies promoted in high profile publications when 
guidelines and reviews are quickly superseded.  There is also a need for sound screening 
programmes for silent arteriovenous malformations.  These occur commonly in the 
pulmonary, cerebral, and hepatic circulations, may haemorrhage, but predominantly result in 
more complex pathophysiology due to consequences of defective endothelium, or shunts that 
bypass specific capillary beds. This review will focus on the new evidence and concepts in 
this complex and fascinating condition, placing these in context for both clinicians and 
scientists, with a particular emphasis on haematological settings.  
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1. Overview of HHT 
 
HHT, also known as Osler Weber Rendu syndrome 1-3, is one of the most common disorders 
to be inherited as an autosomal dominant trait.   Careful epidemiological studies reveal that it 
affects approximately 1 in 5,000 individuals, 4,5 with regional differences, 6 and isolated 
communities displaying higher prevalences due to founder effects. 7 8 
 
HHT was first described as a familial disease characterised by severe recurrent nasal and 
gastrointestinal bleeding with associated anaemia, and visible dilated blood vessels 
(telangiectasia) on the lips and finger tips. The majority of HHT patients are also affected by 
larger arteriovenous malformations (AVMs) in the pulmonary, hepatic, cerebral, pancreatic, 
spinal and other circulations. 1,2,9 These features, presented in more detail within Table 1, are 
used as criteria to diagnose HHT. 2  
 
The spectrum of disease within the HHT umbrella has extended beyond the 
telangiectatic/AVM HHT pathology delineated by the Curaçao criteria. 2  More recently 
recognised features include pulmonary arterial hypertension 10; juvenile polyposis 11; 
pulmonary hypertension in the context of high output cardiac failure secondary to hepatic 
AVMs, when PH may be reversible after hepatic AVM treatment 12-16;  a prothrombotic state 
associated with elevated plasma levels of factor VIII 17, and potential immune dysfunction. 18 
 
Three of the genes mutated in HHT have been identified: endoglin (resulting in HHT1, 
OMIM #187300) 19; ACRVL1/ALK1; (resulting in HHT2, OMIM#600376) 20, and more 
rarely, SMAD4 (mutated in HHT in association with juvenile polyposis, JPHT OMIM 
#175050) 11. Many hundreds of different mutations have been described in HHT families, 
with no common mutation identified (21, summarised in 3).  The mutated gene has some 
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influence on the resultant HHT phenotype, 22-27 although more profound variation in disease 
expression is seen between members of the same family.  
 
Our understanding of why the disease gene mutations lead to the vascular pathology is finally 
advancing, following the generation of exquisite animal models of HHT. 28-31. Attention now 
focuses on aberrant vascular responses to injury-induced angiogenic stimuli, when the 
mutated genes in HHT appear to result in the inability of a blood vessel to mature 
appropriately. 28,30,31   
 
In man, HHT-specific pathology develops in different contexts according to the repertoire of 
susceptibility genes and/or environmental triggers to which each individual is exposed. 
Furthermore, as illustrated in Figure 1 and Table 1, the spectrum of HHT encompasses 
multiple organ systems and within these, numerous forms of disease.  HHT therefore spans a 
vast range of scientific and clinical disciplines, and is an extremely challenging disorder both 
to understand, and to manage. 
 
 
 
 
2. HHT Pathogenesis 
2.1 Insights from HHT patients 
2.1.a) Histopathology 
As in other telangiectatic states 89, the smallest HHT cutaneous telangiectatic lesion appears to 
be a focal dilatation of the post capillary venule in the upper horizontal plexus. 90.  Computer 
reconstruction of serial 1-2mm sections suggest that the dilated post capillary venules enlarge, 
connect with dilated arterioles with loss of the intervening capillary bed, and form 
arteriovenous communications 90, associated with a lymphocytic perivascular cell infiltrate 90.  
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Microscopic telangiectasia are observed not only in the skin, but also in other vascular beds 
such as the pulmonary circulation 91-93 where they are the presumed cause of low grade 
intrapulmonary right-left shunting detectable by contrast echocardiography in the absence of 
macroscopic vascular abnormalities 47-52. 
Large AVMs are thought to arise from these smaller lesions by progressive vascular 
remodelling 90.  For vessels to support arterial pressure, interspecies comparisons indicate that 
there is an optimal wall thickness/ lumen radius ratio to minimise wall stress. 94  When human 
veins are transplanted into arterial settings, adaptation to that ratio normally occurs, 
accompanied by increasing wall thickness. 95  In HHT, however, assumption of a more 
arterial phenotype following establishment of the AV communication is not observed.  The 
vessels within AVMs, and their draining veins are characterised by dilatation with walls of 
varying degrees of thickness even over relatively short segments and disorganised adventitia.  
Medial thinning is seen, though also prominent are areas of focal thickening with abundant 
elastin tissue and a varying contribution of smooth muscle cells 55,92,96,97.  Thus, in spite of 
perfusion at arterial pressure, the vessels immediately beyond the arteriovenous 
communication retain venous type wall structures. 95,98.  
 
2.1.b) Challenges when interpreting clinical data in HHT 
 
Several factors cause difficulties when interpreting clinical patterns in HHT.   First, patients 
are now investigated more thoroughly than in the past, so that older data series underestimate 
the frequency of HHT manifestations, illustrated by the increasing accepted prevalence of 
pulmonary AVMs. 1,93,99,100   Secondly, reporting of individual cases or very small series, 
excluding the denominator from which the selected population was drawn, tends to 
overestimate risks.  For example, many HHT patients understood that they had a high chance 
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of developing an aggressive form of pulmonary hypertension.  While pulmonary arterial 
hypertension does affect a subgroup of HHT patients, the real risk is probably closer to 1-2%, 
16,101 and is genotype-dependant. 102 Thirdly, the majority of affected individuals still remain 
undiagnosed:  In 121 (59%) of 205 consecutive individuals with pulmonary AVMs and HHT 
reviewed at one UK institution, the diagnosis of HHT had not been made previously. 34  
Careful and unbiassed epidemiological studies are required to unmask all HHT-affected 
individuals, especially those with potentially lesser symptoms than in hospital-based series.   
Studies in France, Italy, and Denmark in particular have shed significant light on overall 
prevalence, severity and life expectancy issues in HHT. 
 
2.1.c) Age-related changes in HHT  
 
HHT is not apparent at birth, but evolves with age into a recognisable phenotypic pattern 1,103.  
HHT telangiectasia develop and get worse with age 103,104 (Fig 2a):   Individual cutaneous 
lesions may regress, but overall, as recognised by the families, they generally become more 
prevalent in each individual with time. Currently, cerebral AVM development is thought to be 
complete during childhood, 68 and for most individuals, pulmonary AVMs by the end of 
puberty 105.  Further enlargement of AVMs occurs during pregnancy 106-109, and in specific 
settings.  Understanding why vascular abnormalities arise and develop demands knowledge 
not only of HHT disease gene mutations, but also a broad understanding of normal vascular 
physiology. 
 
Since HHT telangiectases increase with age, it might be expected that haemorrhages will also 
get worse. Gastrointestinal bleeding does appear to increase with age, 103,110 with severe 
bleeding rare in younger patients. 103,110  For nosebleeds, also associated with iron deficiency 
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in HHT (Fig 2b, 2c), and the symptom most frequently associated with impaired quality of 
life in HHT, 111,112 the assumption of age-related deterioration is less clear.  Classical studies 
103, mirrored in our population (Fig 2a), indicate that the proportion of individuals who have 
experienced nosebleeds increases with age.  At an individual patient level however, there is 
major waxing and waning 113,114.  Many individuals with childhood or teenage onset report no 
further bleeds in adult life, such as 14% (23) of the 140 individuals presented in Fig 2a. In this 
series, there was no evidence that the frequency of nose bleeds increased in older age groups 
(Fig 2d).   
 
From a pathophysiological perspective, data on HHT life expectancy are also relevant. Two 
series have been published, a 1973-1997 prospective study of 57 HHT patients, 4 and a 
retrospective analysis of the affected and unaffected parents of 70 HHT patients. 115  In these 
series, there was no evidence for an increase in mortality in patients presenting later in life, 4 
but an excess mortality in patients who had presented with HHT at a younger age, (<60 years) 
4  or in young adults (in a series precluding childhood deaths).  115  These findings are in 
keeping with multiple other series that indicate early mortality due to AVMs, particularly 
cerebral AVM bleeds in childhood and young adults 68,88,116, and pregnancy related maternal 
deaths 55,109, although the article by Kjeldsen AD et al 4, the strongest predictor of early 
mortality appeared to be the severity of nasal or gastrointestinal haemorrhage.  More recent 
life expectancy data of 300 parents of HHT patients 117,  and 562 HHT- patients 118 suggest 
potentially better survival rates, although formal peer reviewed publication is awaited. 
 
2.1.d) Familial patterns of disease  
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While the affected status of younger generations is often difficult to determine due to the late 
onset penetrance, all HHT families described to date illustrate autosomal dominant 
inheritance: Males and females are affected equally, each passing the condition on to 
approximately half of their children, in keeping with the development of disease in 
individuals heterozygous for a mutation in an HHT disease gene.  Several studies 
investigating children with two affected parents, 119-121 or families with two distinct HHT-
causing mutations 122 support in utero or infantile homozygous lethality. 
 
Even allowing for age-related penetrance considerations discussed above, a characteristic 
finding is that there is profound variation in disease expression between different members of 
the same HHT family, 123 suggesting that other genetic and/or environmental influences 
modify the HHT phenotype.  Recognition of this pattern, in contrast to more conventional 
monogenic diseases 124, allowed the development of a model (Fig 3) 125 that has permitted 
identification of non-genetic factors associated with disease manifestations.  17,34  (Livesey et 
al, manuscript in preparation).  Identification of HHT modifier genes is also eagerly awaited . 
126 
 
2.2)  HHT disease gene mutations and TGF-ß superfamily signalling  
2.2.a) Genetics 
 
Currently, five types of HHT are recognised. The majority of HHT patients will have HHT1 
due to mutations in ENG encoding endoglin, 19 or HHT2 due to mutations in ACVRL1 
encoding activin receptor-like kinase (ALK1). 20  One to two percent of cases 127 have 
mutations in SMAD4, mutations that also cause the gastrointestinal epithelial precancerous 
state of juvenile polyposis. 11  There are at least two further unidentified genes that can cause 
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pure HHT, HHT3 between 141.9-146.4Mb on chromosome 5q, 128,129 and HHT4 on 
chromosome 7p between D7S2252 and D7S510. 130   
 
More than 600 different mutations have been found in ENG and ACVRL1 in HHT families (21, 
summarised in 3).  Mutations range from single basepair changes to whole gene (and 
neighbouring gene) deletions. 131  In keeping with the longevity of patients bearing 
heterozygous disease-causing mutations, haplotype analyses of ACVRL1 mutations suggest 
recurrent mutational events occurred 100 to 550 years ago. 8  While founder effects were also 
demonstrated, particularly for the ACVRL1 c.1112dupG mutation proposed to originate in a 
single inhabitant of the Haut-Jura mountains, again the original 21 mutation is estimated to 
have occurred more than 300 years ago. 8  However, worldwide, neither ENG nor ACVRL1 
displays a common mutation with the number of reports of each mutation corresponding to 
first order decay kinetics 132, and mutations occur throughout the genomic sequences. 21 3 The 
situation may be somewhat different for SMAD4, when 25% of mutations appear to arise de 
novo. 127  There were previous reports that SMAD4 mutations in HHT tended to cluster in part 
of the gene encoding the MH2 domain, but a recent more extensive study has shown HHT-
causing mutations also occur in other parts of SMAD4. 127  As would be expected for a disease 
gene frequency of 1 in 5,000, there are occasional families in which two proven HHT 
mutations co-segregate. 122 
 
Individual series describe ENG or ACVRL1 predominance. 22-27  It is not known whether these 
reflect genuine geographical variation, or the clinical referral practice of the relevant HHT 
centres, since there are differences in patterns of HHT between families with HHT1, HHT2, 
and JPHT (see below).  
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2.2.b) Genotype phenotype correlations 
 
All classical features of HHT can be seen in both HHT1 and HHT2, but the prevalence of 
specific vascular abnormalities varies according to genotype. Pulmonary AVMs are more 
common in HHT1 than HHT2, 22-27 though in the relatively small number of SMAD4 patients 
described, the prevalence of PAVMs may be higher still. 127 HHT1 patients are also more 
commonly affected by cerebral AVMs, 23-26 and by microscopic intrapulmonary shunting.  In 
one series, positive contrast echocardiography reflecting intrapulmonary shunting was found 
in 85% of HHT1 patients, and 35% of HHT2 patients 52 compared  to 7% of a control  normal 
population. 47  Patients with HHT2 have a higher prevalence of hepatic AVMs,  23,25-27 and of 
severe disease due to hepatic AVMs 27,70. A single series suggests HHT2 patients may have 
more pancreatic AVMs 9, and develop dermal telangiectasia earlier than in HHT1. 104 There 
are no clear data to suggest that specific mutations within a particular HHT gene confer 
different HHT-related phenotypes.   
 
More recently described non-Curaçao features of HHT demonstrate stronger genotype-
phenotype correlations. Juvenile polyposis (JP) occurs in patients with SMAD4 mutations, 
when it appears to be indistinguishable from JP caused by BMPRIA mutations.  In man (but 
not in mouse 133), pulmonary arterial hypertension occurs predominantly and possibly 
exclusively within HHT2 patients  102,134,135, when it may have a worse prognosis than when 
due to BMPR2 mutations 102.  HHT2 patients are also at higher risk of post capillary 
pulmonary hypertension associated with hepatic AVMs.  12-16 
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2.2.c) TGF- superfamily signalling 
 
The genes mutated in HHT encode proteins that mediate signalling by the transforming 
growth factor (TGF)-ß superfamily (Fig 4).  Superfamily ligands such as TGF-ßs, bone 
morphogenetic proteins (BMPs) , activins, nodals, growth/differentiation factors (GDFs) and 
inhibins normally regulate diverse cellular functions 136 by binding to a heteromeric complex 
of type I and type II transmembrane serine/threonine kinase receptors. There are structural 
and functional differences between the receptors belonging to the TGF-β and BMP groupings.   
For BMP receptors, which have relatively low affinity for ligand, receptor complex formation 
is enhanced by membrane colocalisation, and results in graded responses over wide ligand 
concentration ranges. 137  The TGF-β branch of the superfamily is hypothesised to have arisen 
more recently due to two evolutionary modifications in the type II and type I receptor, 
resulting in a co-operative assembly mechanism permitting a more switch-like mechanism: 
The type II receptor with very high ligand affinity, co-operatively recruits and 
transphosphorylates the type I receptor by direct contact to the ligand-modified N-terminus of 
TßRI 137.    In Smad-dependent pathways, the type I receptor subsequently phosphorylates and 
activates receptor associated (R)-Smads, according to the receptor complex employed.  R-
Smads bind to Smad4 and translocate to the nucleus where they influence transcriptional 
activation with co-activators and co-repressors. Negative feedback loops for these pathways 
include inhibitory Smads (Smad6/7) which target R-Smads for degradation.  Cross talk with 
other signal transduction pathways also occurs 138,139. 
 
 
The HHT mutations suggest that endoglin, ALK-1, and Smad4 are components of a common 
signal transduction pathway that is perturbed in HHT pathogenesis. Endoglin is a relatively 
endothelial specific co-receptor for multiple receptor complexes of the TGF-ß superfamily 
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140,141.  ALK-1 represents an endothelial -specific type I receptor which structurally and 
mechanistically belongs to the BMP branch of type I receptors 137.  ALK-1 can associate with 
at least two type II receptors, BMPR2, and TβRII 142.    In turn, TβRII can associate with two 
different TGF-ß type I receptors in endothelial cells (TßRI [also known as ALK-5], or ALK-
1), activating different  Smad pathways, and apparently resulting in opposing endothelial cell 
responses in terms of  proliferation, migration, and pro or anti-angiogenic gene expression. 
143-147  Different levels of TGF-β1 may activate TβRI/ALK-5 and ALK-1 differentially 143, in 
keeping with the alternate types of receptor complex assembly. 137  
 
Recent HHT concepts include the “balance hypothesis" whereby the HHT mutations modify 
the predominant endothelial TGF-ß type I receptor, Smad pathway, and ultimately endothelial 
cell response, 144-147 and models incorporating BMP9 and BMP10 which are specific ALK-1 
ligands that can also bind endoglin 148-150.  The most recent models indicate a return to TGF-
ß1 rather than BMP9/10 causality in HHT 31. Which ligand-receptor complexes contribute to 
HHT pathogenesis however, remains the subject of intense research 151,152. This is likely to be 
clarified as other HHT disease genes are identified.  
 
 
2.2.d) Generation of abnormal vessels in HHT 
 
The gene mutations indicate that aberrant endoglin, ALK-1, or Smad4 signalling is 
responsible for HHT. Transgenic mice confirm that the mutations cause HHT, since some 
mice carrying one normal and one null copy of the respective gene (i.e. endoglin+/- or 
ACVRL1 +/- heterozygote mice) display features of HHT 151,153-155.   
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The context in which these gene mutations are deleterious, when functioning apparently 
perfectly well for most vessels, has always proved tantalising.   The somewhat simplistic 
concept of a somatic ‘second hit’ 156 whereby the remaining allele was lost in a clone of cells 
has always seemed unlikely in view of the multiplicity of telangiectatic foci, and evidence 
that AVMs in HHT1 patients still express the same level of endoglin ( approximately one half 
normal) as the normal endothelial cells in the same HHT1 patient 97,157.  Large scale studies 
have not been presented, but it is currently believed that in most if not all cases, HHT results 
from endoglin or ALK-1 haploinsufficiency, that is that the remaining wild type allele is 
unable to contribute sufficient protein for normal function. Nevertheless, since even within 
HHT affected vascular beds, the vast majority of vessels appear to develop and function 
normally, perturbation of a context-dependent effect of endoglin or ALK-1 due to 
haploinsufficiency was required. Suggestions that wound healing or angiogenesis might be 
the extra trigger are not new 123, but articles written as recently as 2008-9 left the reader 
unclear as to how this, and the intra-individual and intra-familial variation, could be explained 
132.  
 
Within the last year however, animal models have allowed a clearer dissection of the 
mechanisms by which ENG and ACVRL1 mutations may lead to the abnormal vasculature in 
HHT. These models have employed classical null mice (described for Eng and Acvrl1 with 
embryonic homozygous lethality between E10.5-11.5 153,158-160); heterozygous mice which 
developed variable but more HHT-specific features including nosebleeds, telangiectasia, 
dilated vessels and AVMs 151,153-155 and in some ways represent the most appropriate model 
for human HHT 161; endothelial cell specific knock outs 162;  and mice bearing conditional 
LoxP knockout alleles that for ALK-1 result in a model in which HHT-like vascular 
malformations occurred in a consistent and predictable manner 151.  As in man 90, murine 
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AVMs display venous type wall structures,28,153,158,159,160  and venous molecular signatures. 
30,163,164 
 
The latest data suggest that HHT mutations may be deleterious predominantly during some 
forms of angiogenesis, with specific effects on the stability of newly formed vascular sprouts.  
During angiogenesis, brief periods of endothelial cell activation, proliferation and migration 
are co-ordinated with controlled detachment of the surrounding mural cells (pericytes or 
smooth muscle cells), proteolytic remodelling of the basement membrane and extracellular 
matrix, and expression of endothelial cell survival factors.  Pro-angiogenic factors such as 
vascular endothelial growth factor (VEGF/VEGF-A) differentially regulate defined 
subpopulations of endothelial cells in the angiogenic sprout, independently controlling 
endothelial migration at specialised tip cells, and proliferation in the stalk 165.  Mural cells are 
then recruited to stabilise the nascent blood vessels, 166 with TGF-ß1 strongly implicated in 
this stabilisation process. 167  
Key current concepts for the generation of AVMs and HHT telangiectasia are: 
 Development of AVMs particularly occurs following activation of quiescent 
endothelial cells for example by wounding 28 and/or angiogenesis. 28 31 30   
 In the setting of HHT and an angiogenesis stimulus, there is excessive proliferation of 
endothelial cells, 30,146,147 excessive sprouting of vessels, 30,31,146 with attendant 
formation of AVMs in Eng+/- 30, and ALK-1 deficient 28 mice. 
 HHT mutations (endoglin and ALK-1) impair recruitment of mural cells to vessels, 
160,164 at least in part via reduced endothelial cell secretion of TGF-ß1 168,169 and/or 
reduced TGF-ß1 induced responses. 160,168  Endogenous Smad phosphorylation in 
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mural cells is reduced, 168 but can be restored by exogenously administered ligand 168, 
implying a possible shift in thresholds for receptor activation.  
 Vascular bed specificity of HHT vessel formation may reflect differential basal 
expression levels of endoglin and ALK-1; 170 dynamic down-regulation of endoglin or 
ALK-1, for example in the setting of inflammation; 171,172 different requirements for 
angiogenesis; 28 and/or  differential generation of  reactive oxygen species provoking 
vascular injury:  Endoglin associates with the eNOS/hsp 90 complex 173: In Eng+/- 
mice, eNOS activity is uncoupled, increasing eNOS dependent generation of reactive 
oxygen species.  29,173  
Support for a fundamental role for aberrant angiogenesis and reactive oxygen species in HHT 
disease pathogenesis is accumulating in man, with case reports and small series suggesting 
that anti-angiogenic and anti-oxidant strategies may be of therapeutic benefit in HHT (see 
Sections 4 and 5 below).   
 
 
2.3) Haemorrhage, haemodynamics and iron handling considerations 
 
The abnormal HHT vessels in HHT are prone to bleeding because of their inadequate wall 
structures, and high perfusion pressures.90,174  Acute haemorrhage may be fatal or life-
changing if the haemorrhage is sufficiently large to lead to acute haemodynamic compromise; 
occurs into an enclosed space such as from cerebral AVMs; or prevents essential organ 
function (for example pulmonary AVM bleeding compromising gas exchange). While these 
events can occur in HHT, much more commonly, more modest haemorrhage occurs into the 
relatively open spaces of the nasal cavity/nostrils/atmosphere, or gastrointestinal tract.  Such 
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bleeds are better tolerated acutely, and compensatory mechanisms to replace the lost blood via 
bone marrow release of reticulocytes and enhanced haemoglobin synthesis should occur. 
 
Chronic haemorrhage, however, depletes the body’s intracellular iron stores.  Treatment of 
iron deficiency represents a major component of HHT management, and it is worth briefly 
reviewing some of the newer regulatory insights.   Normally most of the daily requirement for 
iron is met from recycled haem-derived iron through intracellular pool sequestration/release: 
When iron deficient, low portal vein concentrations of transferrin-bound iron (Fig 5) 
downregulate hepatic synthesis of hepcidin (HAMP) reducing internalisation and degradation 
of ferroportin, the sole cellular iron exporter present on all cells, resulting in its increased 
concentration as well as increased export of iron from duodenal enterocytes, and thus 
increasing gut absorption and export of iron from reticuloendothelial storage compartments. 
Where these routes are insufficient to replace iron lost via haemorrhage, iron deficiency will 
result. Sequelae include not only reduced synthesis of haemoglobin (Hb) resulting in anaemia 
and compromised tissue oxygen delivery, but also perturbation of many iron dependent 
cellular pathways. 
 
2.4) Thrombosis and HHT 
 
Age-specific data using a recently developed and validated nose bleed scoring system 33 are 
awaited, but for now, it does appear that epistaxis severity does not increase with age to the 
same degree as the presence of mucocutaneous telangiectasia (Fig 2).  In contrast, 
complications from thromboembolic complications of HHT show clear age-dependent 
increases, 17,34 as in the general population. 175,176 6-7% of HHT patients have pathological  
thromboemboli. 17,177 It seems likely, therefore, that symptoms from the increasing number of 
telangiectases with age are partly off-set by age-related increases in prothrombotic states.   
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2.5) Scientific approach to treatment modalities  
 
While sections 4 and 5 present a clinical approach to HHT treatments, Table 2 presents a 
more scientific approach to possible therapeutic options, based on our current understanding 
of the molecular and cellular basis of HHT. 
 
 
 
2.5.1) Bevazicimub and anti-angiogenesis strategies:    
 
Bevazicimub (Avastin, Genentech Inc., San Francisco, CA) is a recombinant full-length 
humanized antibody active against all isoforms of VEGF-A, isoforms that play differing and 
non-overlapping roles in the induction and patterning of angiogenesis 185.  Bevazicimub was 
introduced into HHT because of a chance observation in a patient with HHT undergoing 
treatment for malignancy.  178  Plasma levels of VEGF had been noted to be increased in HHT 
186, and associated with increased microvascular density in HHT 187.   A subsequent brief report 
of a patient whose hepatic AVMs initially responded 77 has been widely cited, and led to 
substantial interest from patients, though caution was expressed immediately. 78  Topical 
approaches are being used to reduce the serious complications associated with systemic 
treatments, though data from intraocular therapies indicate systemic side effects may still need to 
be considered. 185  
 
5.4.2) Thalidomide – targeting the mural cells? 
 
Thalidomide emerged as a possible anti-angiogenic therapy with a series of Phase II clinical 
studies in cancer 188,189.  As for Bevazicimub, a chance observation in an HHT patient 
undergoing treatment for cancer 190 led to case reports 191 and a small series 31 indicating  a 
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potential role in HHT.   Recent mechanistic data indicate that thalidomide exhibits differential 
effects on immature blood vessel networks 192,193, and dose-dependent effects on angiogenesis 
are proposed 31.   Thalidomide appears to target mural cell recruitment, by increasing endothelial 
expression of  PDGF-B at the endothelial tip cell thus facilitating recruitment of pericytes that 
express PDGFR-b,  associated with increasing pericyte proliferation 31.    In HHT-specific 
studies, in an Eng +/- mouse model, thalidomide normalised excessive vessel sprouting in the 
retina 31.  In addition, in this mouse model in which vessels in the ear and skin displayed 
inadequate coverage by -smooth muscle actin-containing mural cells, thalidomide rescued this 
defect without affecting overall vessel patterning, morphology, or density 31.  The excitement 
engendered by these new mechanistic insights has been accompanied by appropriate reminders 
of thalidomide’s tragic history and toxicity. 193,194  
 
 
 
 
3) Management overview 
 
Several helpful articles have been published in recent years guiding management practice. 
International HHT Guidelines published on line 12 months ago 32 were based on systematic 
assessments of the HHT publications up to October 2006.  The 33 recommendations, 
representing the product of a fairly strenuous review process involving multiple experts,  are a 
very helpful starting point for the field, and are presented in a separate column within Table 1.  
 
The 2006-9 HHT evidence base including the American Heart Association and NICE statements 
on antibiotic prophylaxis 63,64 and HHT-specific responses were included within a 2009 review 
article 3 that also described the increasing spectrum of disease recognised within the HHT 
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umbrella.  Within the last 12 months, in addition to the highly publicised reports on Bevazicimub 
and thalidomide, further evidence regarding hormonal manipulation in HHT, and other new 
clinical data have been presented.  Clinical implications are discussed further below. 
 
 
 
4) Diagnosis  
 
4.1) Clinical diagnosis 
 
The mainstay of diagnosis remain the Curaçao Criteria, international consensus diagnostic 
criteria developed between 1997-1999 2 (Table 1), and recently validated 72.   An individual has a 
diagnosis of “definite HHT” if three criteria are present; “suspected HHT” if two are present, and 
“unlikely HHT” if only one is present.  A crucial issue for families and medical practitioners, is 
that no child of a patient with HHT can be informed they do not have HHT, unless they have 
been shown not to have the specific known causative mutation in their affected family. 
 
The criteria were developed in order to permit a high level of clinical suspicion without leading 
to overdiagnosis, given that nosebleeds (and certain telangiectasia) are common in the general 
population.  The requirement for a third criterion means it is impossible to obtain a definite 
diagnosis of HHT without a more specific visceral feature or a family history.   In clinical 
practice, where an individual from an HHT family has only one further criterion but that 
criterion is a visceral AVM, the diagnosis of HHT is essentially confirmed, though not for 
research purposes.   Conversely, the estimated probability of HHT-affected status for an 
apparently unaffected child of an HHT-affected parent ranges from 0.5 at birth, to  0.22 at 16 
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years and 0.05 at 40 years 103,195,196, ‘Possible HHT’ is preferred for the medical records of such 
individuals when young. 3 32 
 
Haematologists will note that Von Willebrand’s Disease (VWD) can cause diagnostic confusion.   
Like HHT, VWD is inherited as an autosomal dominant trait, frequently causes nosebleeds, and 
can be associated with mucocutaneous and gastrointestinal telangiectasia. Where individuals 
have three Curaçao criteria but there is no personal or family history of visceral AVMs, and no 
known HHT mutation, the author has found it helpful to retain the label “Suspected HHT” while 
investigating VWF status in the family. 
 
 
4.2) Molecular diagnosis 
Molecular diagnostic testing for HHT is available, with an updated list of laboratories offering 
gene testing provided by the HHT Foundation International (see http://hht.org/about-hht/genetic-
testing/).  Mutations detected are available at 21, and have been summarised recently. 3 132  Gene 
testing can confirm the HHT diagnosis for the family, and confirm or refute the diagnosis in 
individual family members.  For patients with definite clinical HHT, molecular testing is not 
required to ‘confirm’ their diagnosis, and at present, does not modify recommended management 
except in the rare setting of SMAD4 mutations, often suspected from the clinical and family 
history (see below). Mutations are not found in approximately 15-20% of HHT families 24,197,198: 
this should not affect a clinical diagnosis of HHT.  Genetic testing is most helpful in the setting 
of a potentially unaffected family member in whom the diagnosis of HHT cannot be excluded 
clinically, particularly if the individual is a parent or grandparent whose status determines the at-
risk status for future generations.  In this setting, identification of a much older affected relative 
with ‘less to lose’ from having a positive gene test may be helpful. 
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An estimated 10-20% of families have genetic variants of uncertain significance, with the 
potential to lead to misdiagnosis 199,200.   In part, this reflects the fact that the majority of 
mutations are unique to particular families.  Furthermore, a high proportion, particularly in the 
ACVRL1/ALK-1 gene, are single base pair changes predicting an amino acid substitution which 
may not be pathogenic.  This is likely to become an even greater problem as next generation 
sequencing technologies are applied to the promoter and intronic sequences of HHT genes.  For 
potential missense mutations, predictions of the severity of amino acid substitutions using SIFT 
201,202 or Polyphen 203 are generally employed, but these can provide disparate results 200.   To 
define a novel missense sequence variant as an HHT disease gene, one laboratory requires co-
segregation studies that indicate an 8:1 likelihood ratio that the sequence variant is associated 
with disease in the family, in addition to amino acid substitution evidence. 200 
 
The recent international guidelines recommended gene testing for adults and children with 
possible HHT, at an 80% level of agreement. 32  In the era of ready access to commercial DNA 
testing, it is important to interpret this statement within the prevailing ethos regarding genetic 
testing.  The consequences of a genetic test differ according to national regulatory frameworks. 
In the US, it is only since the 2008 Genetic Information Nondiscrimination Act (GINA), that 
limitations have been placed on the use of genetic information by health insurers and employers.  
In the UK, the Government and the Association of British Insurers agreed on a moratorium on 
the use of genetic test results in insurance, and it is unclear whether a positive DNA test for HHT 
would lead to additional or even prohibitive weighting when the moratorium on gene testing is 
withdrawn.  The UK Genetic Testing Network (UKGTN) recommends an informed discussion 
with the at-risk individual, before allowing them to decide whether, on balance, a gene test 
would be in their best interests. They also stress that special consideration is needed in children, 
with the UK Clinical Genetics Society (in their 1994 guidelines) advising that in the absence of 
anticipated medical benefit, or likely onset of disease during childhood, formal genetic testing 
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should generally be deferred to allow the “children” to consider the issues for themselves as 
autonomous adults. HHT should not differ from general paediatric recommendations, so the 
updated Clinical Genetics Society Paediatric DNA testing recommendations will be of great 
interest. 
 
4.3) Screening 
4.3.1) General principles 
Screening means testing people who consider themselves well in relation to the disease that the 
screening relates to, and where the stated or implied purpose is either to reduce the risk of future 
ill-health for that individual, or, where risk cannot be altered, to give information about risk that 
is considered valuable 83.   Screening is not the same as investigating a problem or symptom, 
such as breathlessness, or anaemia.  In the setting of HHT, screening refers to testing a member 
of an HHT family (who may or may not be symptomatic for other aspects of HHT) for the 
presence of silent disease such as AVMs in the lungs, liver, or brain.   
 
Due to technological advances, imaging-based screening can identify most important vascular 
abnormalities present in an individual.  This does not necessarily mean that individual was going 
to have a problem from the abnormal vessel/AVM, or if they were to have a complication, that it 
could be prevented. The medical justification for screening regimes in asymptomatic individuals 
from the HHT population depend upon detailed risk-benefit evaluations which are performed to 
determine whether the detection and treatment of an asymptomatic vascular abnormality is likely 
to carry overall health benefits for the patient.  These considerations are recognised to centre on 
the degree of danger posed by particular silent lesions, the safety/tolerability of the screening 
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method; the safety and efficacy of any treatments, and the overall potential advantage offered to 
the recipient in terms of better management. 3 
   
Important general screening concepts have been articulated in recent publications 82,83.   These 
include the four possible outcomes if an abnormality is found by screening, and treated, and the 
tendency of potential recipients to consider only some of the potential outcomes (Table 3) 83.  This 
provides an explanation as to why screening programmes are inherently more attractive to patient 
populations than to clinicians. 
Also detailed, 83 is an explanation of the origin of the differing philosophies regarding screening in 
different countries.   Countries in which the general population has, for decades, been screened 
with annual or periodic checks have a greater acceptance of screening programmes and attendant 
investigations by medical professions, the public, and insurance companies. 82,83   In turn, such 
general population screening programmes reduce the potential harm from medicalisation of 
specific populations unused to regular medical checks.  Recommendations for intensive screening 
programmes derived in such a healthcare culture may be neither appropriate, nor affordable, for 
other healthcare systems.   
 
 
4.3.2) Screening programmes in HHT 
Pulmonary:  Based on evidence of long term technical efficacy and improvement in 
oxygenation achieved by embolization, and the potential for stroke reduction,  pulmonary 
screening has been recommended for all patients with possible or confirmed HHT 204 1 93,205 
32,100.  More recent data demonstrate that PAVM embolization does reduce stroke risk 34, and 
highlight that the majority of PAVM patients are undiagnosed at the time of their PAVM-
induced ischaemic stroke (66.7%) or cerebral abscess (64.3%) 34, emphasising the importance of 
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robust PAVM screening programmes in the HHT population.  While new data also draw 
attention to very rare complications of embolization 206207, and occasional circumstances in 
which it may not be appropriate to embolise PAVMs 55,62, generally the balance of risks and 
benefits remains strongly in favour of screening and subsequent treatment.  The recommendation 
of first line use of contrast echocardiography (Table 1 32) may be modified as a result of recent 
data 47,49; 51  50  48, particularly the study of 52 showing that  85% of HHT1 patients have a 
positive contrast echocardiogram. 52 This clearly has important financial implications as a large 
proportion of these patients will have microscopic disease which is currently not amenable to 
treatment.  Alternative strategies based on CT scans have been proposed, 34,52 and detailed 
considerations are provided elsewhere 66,105   
 
Hepatic: Screening for hepatic AVMs  was recommended to assist the diagnosis of HHT when 
there were fewer than 3 diagnostic criteria, and genetics tests were unhelpful. 32  Recent data, 
however, indicate that this does not improve the diagnosis of HHT 72 but there may be new 
indications for Doppler studies in ALK-1/HHT2 families in whom prediction of individuals at 
greater risk of high output cardiac failure (based on hepatic artery diameter and presence of 
regenerative nodular  hyperplasia) could lead to different follow up regimes. 70 
 
Cerebral: The recent International Guidelines recommended screening adults (77% agreement) 
and children (64% agreement) with possible or definite HHT by cerebral MR, followed by 
referral to centres with neurovascular expertise for consideration of invasive imaging and 
consideration of treatment. 32   These recommendations were made recognising that there was no 
evidence of treatment effectiveness for asymptomatic individuals; that asymptomatic AVMs 
discovered during screening of HHT may carry a more favorable progress than symptomatic 
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AVMs; and the not inconsiderable risks of diagnostic tests  (0.5% risk of permanent stroke per 
diagnostic angiogram) 32.  
 
Such conclusions were not reached by all authors of large data series 88,208 and remain 
controversial, not least because neurovascular treatment centres are acutely conscious of the risks 
and limitations of treatment modalities.  Recent treatment data series for nidus AVM by 
embolization, 68 stereotactic radiotherapy 209, and microsurgery 210 confirm the frequent need for 
multimodality treatments as utilised in specific centres, each with its attendant risks. 211  Issues 
regarding communication of expectations, treatment programme duration and limitations, and 
life style adjustments have been recently presented from the patient’s perspective, 69 and are 
clearly highly challenging even to individuals who have already had a haemorrhagic stroke and 
represent a particularly high risk group for a future bleed.  69 
 
Wide-scale screening programmes will raise these issues for high proportions of screened 
individuals, since cerebral vascular malformations may be present in up 22.8% of patients 212,213, 
with high flow AVMs in 3.7-11% 88,212,213. We find that even where an asymptomatic individual 
is in a higher risk group (having a family history of cerebral haemorrhage) for whom our group 
suggest MRI scans based on the advice from the late Prof Pierre Lasjaunias, 55,208 the decision to 
undergo this study is not straightforward.   
 
Children: The international guidelines recommend screening children from HHT families for 
CVMs (64% agreement) and PAVMs (children not considered separately to adults). 32  There are 
clearly tragic cases of HHT-related deaths and disability in youngsters,  {Easey, 2003 #2715; 
Krings, 2005 #3707; Krings, 2005 #3707; Curie, 2007 #3445; Cullen, 2006 #3706} 81 34,79 and 
children with symptoms require investigation, and treatments guided by knowledge of HHT 
pathology.   
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For pulmonary AVMs, the guidelines 32 and subsequent recommendations 216 appear to be 
predominantly based on symptomatic children in series derived from a specialist paediatric 
centre.   As previously presented, 34 based on the paucity of evidence for childhood 
complications from silent PAVMs in previously healthy children, our group do not see sufficient 
indication to conduct a formal screen before the time of peri-pubertal PAVM growth and 
maturation, and resolution of the ethical, familial, and radiation issues that influence paediatric 
discussions. 34 3 
 
While the 64% agreement highlights the level of controversy surrounding the recommendation 
for cerebral screening in childhood 32, the issue needs to be considered carefully.  The reason is 
that a particularly high risk cerebral vascular abnormality has been identified in children from 
HHT families. 34 cases of AV fistulae (spinal or cerebral) were identified in one European 
referral centre’s 15 year experience. 68  All except two cases, occurred in children aged less than 
7 years old 67,208(Fig 6),  suggesting the possibility that few individuals survive the presence of 
these lesions (Pierre Lasjaunias, personal communication 2007).  In contrast, typical (nidus type) 
macroAVM and microAVM presented in older ages (Fig 6).  Other groups have also 
demonstrated AVFs in childhood HHT series 157.  For AVF in children, however, interventional 
risks were high.  In the Bicêtre series of 31 children who were usually highly symptomatic, 
treatment related risks included 6.5% mortality and 6.5% new permanent neurological deficit. 68  
The complete occlusion rate was 38.7% of survivors 68 although symptomatic benefit resulted 
from partial treatment. 68  
 
Extrapolating these data to asymptomatic children in HHT families is extremely difficult.  All 
parents will hope that a screening scan will not detect a vascular malformation in their child 
and may restrict their considerations of some of the possible outcome (Table 3, 83).  Many 
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however, will have to face the possibility of treatments for a child that appears currently well; 
treatments aimed at reducing the likelihood of complications for which there are very few 
data in asymptomatic children; and treatments that carry substantial mortality and morbidity, 
yet may not achieve the complete occlusion desired. 69 In this delicate and emotionally 
charged area of uncertainty, public health policy and prevailing population backgrounds can 
lead to substantially different interpretations of risk benefit considerations for and by the 
individual.  For health care systems where the current evidence base would not support the 
introduction of screening programmes, this author proposes that an appropriate way forward 
would be to seek further data through research-orientated studies, pending country-specific 
guidance from paediatric-based groupings.   
 
5) Treatment 
5.1 AVMs 
Details of the treatment of each type of AVM are beyond the scope of this text: the interested 
reader is referred to the references in Table 1, and recent treatment texts for general aspects of 
HHT 3 32 and AVMs in cerebral 68209 210 211 ,  pulmonary 59,60,66,105, and hepatic circulations 73,74 . 
 
5.2) Management of iron deficiency anaemia  
In this chronic condition, it is essential to reserve treatments carrying higher risk, for patients 
with the most severe disease.  Maximal attention to local therapy and iron replacement 
manoeuvres discussed below are required, potentially with stratification according to ongoing 
transfusion requirements 217,  before proceeding to consideration of second line, or experimental 
therapies (Table 4)..   
 
5.2.1.Epistaxis and gastrointestinal bleeding: 
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Conventional management of iron deficiency anaemia leads to referral to gastroenterologists for 
endoscopic therapy, and this is  also encouraged with HHT 110, noting the limitations of 
endoscopic treatments 218, and recommendations for a limited number of therapy sessions.  32  
Before referring to a gastroenterologist, however, a careful history of nose bleeds is warranted:  
A recent study of 915 HHT-affected individuals indicated that a severity score based on presence 
of anaemia and need for transfusion in addition to four other independent factors (nose bleed 
frequency; duration; gushing or pouring quality; or the need for medical attention) was a 
significant predictor of invasiveness of therapy required for nosebleeds 33.  These data, together 
with the new evidence that nosebleed frequency correlates with iron and transfusional need (Fig 
2), highlight the need to obtain good ENT-based reviews of anaemic patients, for specialist ENT 
treatments as outlined in Table 1.  
 
 
5.2.2 Anaemia:  
It is unusual to be able to abolish nasal and gastrointestinal bleeding in HHT. Prevention and 
management of anaemia becomes paramount in at least a third of HHT patients.  Dietary advice 
for iron containing foods, and identification of oral iron preparations that suit the individual are 
important steps to reduce the need or frequency of blood transfusions or iron infusions required 
by severely affected individuals. Unfortunately, it remains commonplace to find patients 
receiving intravenous iron or transfusions with minimal or no attention to oral iron intake. 
Dietary iron sheets are available on line, 219 220 and patients should seek to meet more than the 
recommended dietary allowance of iron.  Where high dose iron tablets are not tolerated due to 
gastrointestinal side effects, lower dose regimes using small volume syrups or ‘prophylactic 
dose’ iron are preferable to no added oral intake.  
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5.2.3 Hormonal manipulation: 
To date, the only randomised placebo-controlled trials to demonstrate benefit in prevention of 
HHT haemorrhage have involved hormonal manipulation in the form of oestrogen-progesterone 
46,  and tamoxifen 46 (Table 4). The high dose oestrogen-progesterone regime is poorly tolerated 
particularly in men, and there are increasing concerns about thrombotic side effect profiles.   
More recently,  a double-blind, placebo-controlled trial of the anti-oestrogen tamoxifen 46 
demonstrated a significant reduction in the frequency of epistaxis in the treated group, 
accompanied in many cases by either a rise in haemoglobin or reduction in transfusion 
requirements.  There are good long term safety data for the use of tamoxifen in prevention of 
breast cancer, though there is concern regarding endometrial hyperplasia, a problem that may be 
reduced by the raloxifene, a selective estrogen receptor modulator for which there are also new 
data regarding beneficial effects in HHT 45.  
 
5.3.4 Antifibrinolytics and prothrombotic agents 
Therapeutic manipulation of coagulation and fibrinolytic pathways is often employed to try to 
limit blood loss in HHT 41,42,181,182. These therapies have not yet been supported by data from 
randomized controlled trials. Recognition that venous thromboses occur in HHT, associated in 
many cases with coincidental inheritance of prothrombotic genetic variants such as FV Leiden, 
has raised concern regarding thrombophilic risk with these agents. 17   It was therefore suggested 
that routine measurement of FVIII, FV Leiden, and other thrombophilic markers in HHT patient 
assessments may assist individualised risk-benefit considerations before prothrombogenic 
systemic treatments are given. 3,17  
 
 
5.3.5 Antioxidants 
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There are recent uncontrolled short term data demonstrating efficacy from oral N acetyl cysteine 
in a large series of 43 HHT patients 40 (Table 4).  This specific drug is not currently licensed in 
many countries but in general, antioxidants have favourable side effect profiles during long term 
use. 
5.3.6) Angiogenesis based- treatments 
The eagerness to treat, and recognition that in rare diseases, a handful or even single cases of data 
merit high impact journal publication  (Table 4), naturally encourages the exuberant use of agents 
whose potential roles compared to the best available existing treatments, and safety profiles are yet 
to be determined in HHT.  Side effect profiles, and better understanding of the full implications of 
such treatments 78, are likely to be crucial in determining whether the use of any efficacious agents 
becomes more widespread within the HHT patient population. 
 
For the currently available drugs, systemic treatment can result in serious adverse events: Frequent 
and unpredictable side effects for antiangiogenic strategies include thrombosis, haemorrhage, 
decreased wound healing, and organ perforation.  223 The most commonly reported Bevacizumab-
related toxicities were bleeding/haemorrhage, hypertension, proteinuria, and venous or arterial 
thromboembolic events 224.  In addition, the British National Formulary emphasises the risks of 
gastrointestinal perforation and fistulas, and  that treatment should be withheld before elective 
surgery and avoided for at least 28 days after major surgery or until the wound is fully healed 184. 
Experience within HHT is too limited (Table 3) to address whether the resistance to VEGF-
targeted therapy emerging in cancer settings will also occur during long term use in HHT 185.   For 
thalidomide, as for Bevazicimub, there are safety concerns in long term modulation of the 
angiogenic process so critical for normal wound healing, menses, and enterocyte and neural 
viability. Thromboprophylaxis is recommended for at least the first 5 months of treatment, 
especially in patients with additional thrombotic risk factors 184 and pregnancy must be avoided 
184.   
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The identification of these agents’ activities as targets in HHT is anticipated to lead to further and 
safer therapeutic options.  For now, however, use of these agents should be restricted to their 
evaluation in carefully selected, consenting patients in randomised control trials currently 
recruiting within experienced HHT centres. 
 
5.4) Non haemorrhagic settings in HHT 
5.4.1)  Deep venous thromboses- prophylaxis and treatment 
In contrast to advice given to patients in earlier years, it is now well recognized that there are 
settings in which anticoagulants (and/or antiplatelet agents) are required 32 in order to prevent 
major ischaemic or thromboembolic sequelae.  Prophylactic dose anticoagulation for example is 
required during high risk periods for venous thromboemboli (VTE)17, particularly for HHT 
patients hospitalized with pulmonary AVM-induced brain abscess 17. Where VTEs occur, 
treatment dose heparin  and warfarin can be given. In our experience, anticoagulation is tolerated 
surprisingly well by many patients,  though patients should understand that their nosebleeds are 
likely to get worse, and there may be concerns (none proven to date) about haemorrhage from 
internal organs.  In our group’s experience, long term prophylaxis or primary prevention strategies 
are more difficult to justify in the setting of HHT. 225 
 
5.4.2)  The HHT patient with a stroke: 
 
HHT-affected families should be aware that in the event of stroke-like features, their doctors may 
need to be alerted to their three potential stroke types (haemorrhagic, ischaemic and infective) , 
and that neurological symptoms in HHT, including stroke,  are more likely to be due to 
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paradoxical embolization through pulmonary AVMs than to complications of cerebral vascular 
malformations. 34,87,88 
 
Modification of local stroke management protocols 226 may be required, including consideration of 
early MR imaging to assist the diagnosis of brain abscess.   In the case of ischaemic stroke, while 
in our experience anti-platelets are tolerated surprisingly well by many patients, the likely 
presence of AVMs would be considered an absolute contraindication to thrombolysis were HHT 
to be recognised 227.   
 
5.4.3 )  The pregnant HHT patient  
 
Based on small series and case reports, many women were being advised pregnancy was too 
dangerous to contemplate, and vasectomies or terminations advised.  A recent study of 484 
pregnancies in 199 women with HHT and PAVMs demonstrated that that the majority were able to 
have a normal pregnancy 55. That said, a small proportion of women did experience life-threatening 
complications including PAVM bleed; stroke; myocardial infarction and pulmonary embolus.  In this 
series, 1.0% (95% confidence intervals 0.13, 1.9%) of pregnancies resulted in maternal and fetal 
death, with all deaths occurring in women previously considered well 55.    
Importantly, in women experiencing a life-threatening event, prior awareness of HHT or PAVM 
diagnosis was associated with improved survival 55.    General recommendations for the management 
of women with HHT therefore include management as “ high risk pregnancies”;   maternal education 
to consider haemoptysis of any degree or sudden severe dyspnoea as a medical emergency prompting 
urgent hospitalization; and specific obstetric, and obstetric anaesthetic issues discussed in detail 
elsewhere 55.    
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5.4.4  Dental treatments 
For patients with PAVMs and HHT, antibiotic prophylaxis prior to dental and surgical procedures 
was recommended, based on the endocarditis paradigm 228 32. The evidence for an association 
between oral microorganisms and brain abscess was strengthened further 34, but in the interim, the 
American Heart Association 63 and British NICE guidelines 64 were published indicating that 
antibiotic prophylaxis is no longer required for most patients with structural heart disease at risk of 
infective endocarditis, and leading to confusion for dentists and medical practitioners of HHT/PAVM 
patients.  A subsequent article explored why PAVM/HHT patients do not fall into the groups 
considered by AHA/NICE, and provided recommendations to reduce the risk of dental bacteremias 
including the use of antibiotic prophylaxis prior to dental procedures 65.    
 
5.4.5 Air flights 
While there are theoretical concerns regarding in-flight exacerbation of hypoxaemia, and risk 
of venous thromboembolism, there are very limited published data in HHT. The author's 
experience is that individuals with significant PAVM-induced hypoxaemia have flown 
without seeking medical advice, and suffered no ill-effects.  There are reports of ischaemic 
stroke 34 and deep venous thrombosis 17 occurring immediately after transatlantic flights.  
However two cases of in-flight PAVM haemorrhage (one haemoptysis, one haemothorax) 
have also been reported recently 229.  Further data on flight toleration in a large series of HHT 
patients will be available shortly (Mason and Shovlin, m/s in preparation) and should assist in 
providing an evidence base for recommendations. 
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6) Perspective 
 
For families with HHT, the recent advances in scientific and medical understanding of their 
condition are encouraging after the decades of limited advances.  There are genuine hopes for 
improved and targeted treatment modalities, and emerging evidence that existing strategies 
are already offering affected individuals a better medical outlook than their grandparents.   
 
Yet there are others for whom the deluge of new and frightening information holds concerns.  
As one attendee of the 2009 UK HHT Family Meeting confided, “It is not hard to foresee a 
time when the label of HHT is worse than the condition itself”.  As clinicians and scientists 
seek to improve health outcomes in HHT, the voices of the HHT family members are the 
most important to be heard. 
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TABLE 1 
 
Curaçao Criteria  % Diagnosis† Potential                                       Management recommendations in                       Data published post g/line development  $ 
       Complications   2009 guidelines 32  
 
 
1) NOSEBLEEDS       
    (EPISTAXIS)  90 Evident Anaemia; massive 
        acute haemorrhage =  
       
       
 
 
 
 
2) TELANGIECTASIA   
Lips; oral cavity 
 fingers; nose  80 Evident Usually cosmetic,         Tamoxifen RCT 46  
     may haemorrhage                                                          
 
 
3) VISCERAL LESIONS, such as 
a) Gastrointestinal telangiectasia   15-30 Endoscopy Haemorrhage (chronic)  
  (with or without bleeding)   (upper /lower)  Anaemia    
 
 
 
 
 
 
b) Pulmonary AVMs  50  CXR/CT  Most asymptopmatic 
    Echo R-L shunt:  
       Hypoxaemia +/- dyspnoea; 
      Stroke/ TIA* 
      Brain abscess 
      Migraine. 
     Decompression illness;  
   Haemorrhage  
     Haemoptysis 
     Haemothorax  
rare except specific  
circumstances  
 
 
Screen asymptomatic adults and children. 
Transthoracic contrast echocardiography as intital 
screening test. Embolization for all adults with 
PAVMs, and symptomatic children, based on feeding 
artery generally 3mm or greater, though targeting of 
smaller PAVMs may be appropriate. To be performed 
in HHT center of excellence, particularly for higher 
risk states of pregnancy and mild-moderate 
pulmonary hypertension . Surgery only in 
management of life threatening bleeding. Antibiotic 
prophylaxis as per AHA recoemmendations for 
prevention of bacterial endocarditis . IV air through  
iv access, and Scuba diving  to be avoided. (Life long 
since 90% of CEs remained positive post Rx ; also for 
HHT if PAVMs not excluded).  Long term follow 
up: Post embolisation CT at 6-12 months then 3 
yearly; small untreated, or CE positive, 1-5 yearly.   
New data on echo grading  and predictive values 47-51, and 
frequency of positive results 52.  New natural history data 
re stroke/brain abscess (risks independent of PAVMs size  
imply need to treat all PAVMs feasible 34; migraines 53,54 ; 
pregnancy rupture 55.  New efficacy data for embolization:  
prevention of stroke 34; reduction in migraines 56. New 
recanalisation data  57,58.   Technical improvements in 
embolisation treatment devices (Amplatzer devices 59,60).   
Further data on post embolization systemic arterial 
supply without haemoptysis 61 ; Embolization with pre-
existing pulmonary hypertension 16,62).  Dental issues 
AHA 63 and NICE Guidance 64, but reconsidered and Abs 
still recommended 65.   SCUBA diving: alternative to 
complete cessation discussed  66.   
Annual Hb or haematocrit screen over 35 ys. Oral 
or iv iron  first line for mild anaemia. Consider 
systemic hormonal or antifibrinolytic therapy in 
selected patients to limit GI blood loss .   One or two  
endocopic treatments, but avoid multiple attempts.  
Thrombogenic concerns in HHT published  17, also 
relevant to stated concern of thrombogenic risks  of 
eythropoeitin 32 See also new data from epistaxes 
medical treatments above. 
New validated severity scoring system  (33; see text). High 
proportion without medical or ENT review 33,34. New 
data: Surgery and embolization  35-39., medical 
treatments 31,40-45 
 
Acute:  First aid; packing (self + variety of 
commercial devices).  Recurrent:  
Humidification, topical lubricants.  2nd: Laser 
therapy; 3rd : Surgery (esp. septal dermatoplasty; 
Youngs) by dedicated expert ENT surgeon (No 
role for arterial ligation/ embolisation) 
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c) Cerebral vascular malformations  ¶ 10-20 MRI  Haemorrhage depends on type: 
   Angiography  AVF>macro>micro≥tel.  
    For AVM  (?0.5% per annum, 
           i.e. lower than general popn.    
     Headache 
   Epilepsy 
   High output cardiac failure (paeds) 
 
 
 
 
 
 
d) Hepatic vascular malformations 30-70 Doppler US Most (>90%)  asymptomatic70  
        CT +/- invasive Hepatic AVMs:   
    High cardiac output +/- failure; 
       Post capillary pulm. hyp.;  
       Focal nodular hyperplasia  71 
    Hepato-portal VMs:  
      Portal hypertension 
    (ascites; varices; encephalopathy) 
    Porto-hepatic VMs 
    Biliary ischaemia, encephalopathy 
     
 
e) Spinal AVMs <1% Spinal MRI Haemorrhage;   
    Paraplegia (acute, subacute or progressive)  
   SOL +/-  steal: Pain, asymmetric growth 
   Progressive myelopathy in adults 
 
 
4) FAMILY HISTORY 
 
 
 
Legend: The four separate Curaçao criteria are spontaneous recurrent nosebleeds; mucocutaneous telangiectasia (multiple at characteristic sites: fingertip pulps, lips, oral mucosa, 
tongue); Visceral involvement  such as gastrointestinal involvement;  pulmonary, hepatic, cerebral or spinal AVM;  and a first degree relative affected according to these criteria.  $  
Also see new data regarding general screening 82 83, and radiation sensitivity in children 84 85,86.  Other viscera affected include pancreatic telangiectasia (31%) and AVMs (11%) of 35 
consecutive adult HHT patients screened (no relevant symptoms) by contrast enhanced multidetector CT 9; with case reports for other viscera.  * Neurological symptoms in HHT are 
more likely to be due to pulmonary than  cerebral  vascular malformations 34,87,88 
AV fistulae (AVF)  
Macro (nidus type) AVM 
 Micro AVM (<1cm) 
Capillary telangiectasia 
Other forms can occur 
Hepatic artery – hep. vein 
Hepatic artery – portal vein 
Portal vein – hepatic vein 
Screening to facilitate diagnosis of HHT. Avoid 
liver biopsy in suspected or proven HHT.  Avoid 
hepatic artery embolization  
Consider referral for liver transplantation  if 
ischaemic biliary necrosis; intractable heart failure; or 
intractable portal hypertension.
New pregnancy considerations  55.  Better appreciation 
of time of development in children 67. New data on HHT 
specific mortality/morbidity of treatments in children 68.  
New patient perspective 69 
 
Screening of asymptomatic individuals  (children 
from 6 months or when reviewed) recommended.  
Obliteration methods: Variety possible 
(embolisation; microsurgery, sterotactic radiotherapy 
or combination), and no dedicated evidence for HHT 
population. Evidence from  non HHT populations 
indicate varying effectiveness .  All cause significant 
procedural risks, and management in expert centres 
with neurovascular experience advised.  If pregnant 
and asymptomatic CAVM, defer treatment until after 
delivery. 
Hepatic AVM screen did not add to criteria 72. For more 
detailed recommendations see 73. New data on prevalence 
70; association of enlarged hepatic artery and focal nodular 
hyperplasia (13%) with high cardiac index 70;  Long term 
liver transplant  effectiveness 74,75, but evidence of 
recurrence in transplant 76.  Bevazicimub case report 77 but 
cautionary comments 78 
Further  descriptions and case details in  68 (7 cases 
presented symptomatically aged 1 month -6 ys 67 ), and 
case reports + literature reviews  79 (2 cases),  80; 81.  New 
pregnancy considerations 55.   
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Table 2: Potential HHT Therapeutic Strategies 
 
Potential strategy Comment
A) Targeting the vessel  
1. Correction, or partial correction of the gene defect in 
endoglin, ALK-1  or Smad4: 
Substantial difficulties for a finely tuned system with 
exquisite dynamic regulation at incompletely 
understood timepoints 
2. Targeting the stimulus precipitating an abnormal 
vascular response  
 
a) Direct anti-angiogenesis strategies 
 
b) Indirect, identifying and reversing the triggers 
precipitating angiogenesis  
 
c) Indirect, reducing the triggers precipitating 
vascular damage, such as oxidant stress, or 
aberrant immune responses. 
 
 
a) Bevazicimub: (anti-VEGF monoclonal Ab.) 178  77 
 
 b) Trauma? Inflammation? Note chronic infection in 
non-HHT settings precipitates exuberant formation of 
aberrant bronchial vessels 105 
 
c) N-acetyl cysteine (NAC) 40 and interferon 179,180 
 
3. Allow defective signalling and stimulus, but 
promote a corrective response to the TGF- deficient 
state in mural cells 
 
Mechanism proposed for thalidomide  31.  Note at 
higher doses, thalidomide acts as an inhibitor of 
angiogenesis.   
 
4. Obliteration  or removal of vessels once formed   a) Laser therapy for telangiectasia; 
b) Embolization of  pulmonary/ cerebral AVMs 
c) Surgical resection (esp. cerebral AVMs); 
d) Organ transplantation (esp. hepatic AVMs) 
B) Targeting haemorrhage  
5. Prevention of excessive haemorrhage with 
prothrombotic strategies
Antifibrinolytic agents, such as local or systemic 
tranexamic acid 41,181 and aminocaproic acid 182.  
6. Combination approaches- Hormonal treatments 
 
a) high dose oestrogen-progesterone RCT 183    
b) anti-oestrogen tamoxifen: RCT 46 
c) selective oestrogen receptor modulator (SERM) 
raloxifene 45 
Incompletely understood mechanisms. Likely to 
include prothrombogenic effects (noting pathological 
thromboemboli recognised side effect of  all agents 
184) . Possibly direct modulation of endothelial cell 
and vascular function. 45 
 
7. Treat iron deficiency anaemia See text 
 
C) Targeting other complications in selected patients 
8. Circumstance specific, e.g. 
a) Pregnancy 55 
b) Dental treatments: post AHA/NICE 63 64 
guidance for HHT/PAVM patients 65. 
9. Pathology-specific, e.g. 
c) Venous thromboemboli – see text 
d) Antiplatelet therapy for standard indications 
(ischaemic stroke, ischaemic heart disease, 
paradoxical atrial fibrillation etc.)- see text 
 
 
 
a) Pregnancy: HHT-specific management in view 
of life-threatening haemorrhagic and thrombotic 
events, and improved survival with prior 
awareness of HHT or PAVM diagnosis 55.   
b) Dental:  PAVM/HHT patients do not fall into the 
groups considered by the AHA 63 or NICE 64.  
Recent guidance included improving dental 
hygiene and the use of antibiotic prophylaxis 
prior to dental procedures 65. 
 
 
Legend:  RCT, randomised control trial.  Conventional treatments within Group A focus on option 4, 
and within Group B on option 7, with randomised control trial evidence for option 6 (hormonal 
treatment).  Options 2 and 3 remain experimental and are currently dependent on the use of highly 
toxic agents. The author is unaware of any plans to attempt option 1. 
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Table 3: The 4 possible outcomes of screening for the individual  
 
 
       Benefit   No benefit * 
No harm a. Screening and treatment help. 
No side effects or harm 
b. Screening and treatment no 
help. No side effects or harm 
Harm c. Screening and treatment help, 
but side effects or harm 
d. Screening and treatment no 
help, but side effects or harm 
 
Legend: Adapted from table in reference 83. * In the setting of these discussions, the AVM was never 
going to cause that individual a problem. As described in 83, individuals want to be in group a), realise 
they might be in groups b) or c), and try to ignore the chance that they personally will be in group d). 
Clinicians are more likely to include the possibility of d) in their evaluations. To minimise harm, it was 
advised that balanced information should be provided to all potential recipients to ensure that they 
understand the benefits without overlooking the potential negative aspects of the screening/treatment 
programme. 83   
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Table 4   Summary of new trials reporting benefit from new HHT treatments 
 
Treatment    N=  Comparison group  Comment 
 
A) Randomised control trials in HHT  
Tamoxifen  46  10 vs 11  untreated controls  previous RCT evidence for hormones  in GI bleeding (50 mcg of      
              ethinylestradiol plus 1 mg  norethisterone) 183 but not epistaxes 221 
B) Observational 
 
i) ENT procedures ¥ 
 
Septodermatoplasty35;   301  KTP laser  alone 
Fibrin sealant nasal packing 36  64    KTP  laser  alone 
Argon plasma laser 37   43 
Embolization 38    12 
Septectomy  39       9     
 
ii)  Medical agents 
 
N- acetyl cysteine (NAC) 40  43  None    Prospective 
Tranexamic acid 41   14  None    Prospective 
  42   10  None    Retrospective 
Thalidomide* 31   7  None     
 
Avastin (bevazicimub) 
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Systemic 77   1 liver case  See follow up cautionary comments 78 
 
Topical 43   10 vs 9   topical as adjunct to KTP laser 
 44   1   Topical 
          
Raloxifen 45  19   In vitro, stimulated endoglin and ALK-1 promoter activity, increased protein expression and modified EC function 
2nd generation selective 
 estradiol receptor antagonist 
 
 
§ post HHT Guidelines evaluation;  ¥/ observational studies where N<5 not reported. * Case reports included 222  191 
 
 
 
 
 
 
 
FIGURE LEGENDS 
 
 
Figure 1: Circulatory sites of vessels commonly affected by HHT  
 
Schematic of systemic and pulmonary circulations indicating vascular beds commonly 
affected by HHT.  Red arrows denote AVMs.  PV denotes portal vein. The pulmonary 
circulation indicates pulmonary AVMs, and distinguishes sites of pulmonary arterial (PAH), 
and post capillary (PCPH) pulmonary hypertension.   The hepatic and portal circulations 
indicate the 3 anatomical forms of aberrant hepatic vascular communications: 1: hepatic 
artery to hepatic vein (arteriovenous, associated with high output states and PCPH), 2: hepato-
portal (hepatic artery to portal vein, associated with portal hypertension), and 3, porto-venous 
(portal vein to hepatic vein).  Note that conventional hypertension, i.e. the blood pressure in 
systemic arteries, does not relate to either pulmonary or portal hypertension.    
 
Figure 2: Cross section of epistaxis in an HHT population: 
Maximum nosebleed severity described by HHT/PAVM patients in 34, a population without 
an ENT ascertainment bias. a): Cumulative frequency diagrams of nosebleeds and diagnostic 
telangiectasia.  Red solid line: age of onset of nose bleeds as described by patient ‘pre 
school’; child; teenager; and adult ages.  Black dotted line: prevalence of nosebleeds at age 
groups: Note the lower prevalence in adults as nosebleeds regressed in 14% of affected 
children and teenagers. Blue telangiectatic line represents survival curve modelling based on 
the presence of diagnostic telangiectasia at particular ages when PAVMs were diagnosed 
(defined by physician).  b): Maximum nosebleed severity indicating % of population (bars) 
and actual numbers per group.  c): Maximum nosebleed severity data reported in different age 
quartiles.  Note that in contrast to the prevalence of skin and mucosal telangiectasia in a, there 
is no clear increase in number of patients reporting nosebleeds in these more severe categories 
with age.  d): Use of iron supplements (bars) and transfusions (triangles) stratified by 
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nosebleed severity.  Note more frequent nosebleeds associated with a higher use of iron 
(p=0.002). 
 
 
Figure 3: HHT and the spectrum of genetic disease     
HHT is a monogenic disease and lies at the right hand of the spectrum.  Nevertheless, HHT, 
or a particular characteristic of HHT in an affected individual may depend upon other genes 
or environmental factors influencing the phenotype.  Originally published as Fig 1.30 in 125.    
 
Figure 4: TGF- superfamily signalling 
Adapted from original figure published in 128 
 
Figure 5: Iron homeostasis 
Most of the 20mg daily requirement for iron is met from recycled haem-derived iron, and not 
intestinal absorption.  Both processes are regulated by hepcidin (HAMP), a hormone 
synthesised predominantly in the liver that induces internalisation and degradation of 
ferroportin, the sole cellular iron exporter present on all cells.  Iron not incorporated into 
proteins is complexed into non-toxic transport or storage protein aggregates, with transferrin 
(FeTf; Fe2Tf) in serum, and ferritin (Fe>100ferritin) in cells.   
 
Figure 6 Age at presentation of the four different encountered cerebral vascular 
abnormalities in HHT.  
Presentation ages are represented on a logarithmic scale, with black diamonds representing 
the mean age of presentation. 67 (Needs permission).   
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